How to evaluate the effect of veentuzumab/presidium after three repeated doses

Enfortumab is an antibody-drug conjugate primarily used to treat patients with locally advanced or metastatic urothelial cancer (bladder cancer) who have previously failed immune checkpoint inhibitors and platinum-based chemotherapy. As an innovative drug that has attracted much attention in the field of oncology in recent years, it combines with Nectin-4, a molecule highly expressed on the surface of urothelial cancer cells, to deliver cytotoxins directly to tumor tissues, thus exerting a precise killing effect. With the introduction of this drug in China, one of the common concerns of patients and their families is how to scientifically evaluate the efficacy after three treatments.

From international experience, the evaluation of the efficacy of tumor drugs mainly relies on imaging examinations, improvement of clinical symptoms, and laboratory indicators. ForEnfortumab, usually after completing several treatment cycles, doctors will arrange imaging follow-up, such as CT or MRI, to observe changes in tumor volume. This is a key way to determine whether a drug is producing objective relief. If the tumor shrinks or remains stable, the drug is considered to be working. However, it should be noted that the response speed of different patients may vary. In some patients, the effect can be observed after the first few infusions, while in other patients, it may take longer to appear.

The improvement of clinical symptoms is also an important reference. For patients with advanced urothelial cancer, pain relief, improvement in physical status, and improvement in quality of life are often the most intuitive manifestations of the efficacy in the early stages of treatment. If the patient's symptoms are relieved and his activity tolerance is improved after three treatments, this is also one of the positive signs of efficacy. At the same time, laboratory indicators such as blood tests, changes in kidney function and liver function can help doctors judge the overall impact of drugs on the body.

In daily clinical practice, the evaluation after three treatments belongs to the preliminary observation stage, and whether to continue taking medication often depends on the comprehensive results. If the drug is well tolerated and there are positive signs on imaging or symptoms, doctors generally recommend continuing maintenance therapy.

Reference: https://www.padcev.com/